97 studies were found. Here are studies 1 to 50.

1.		Recruiting	Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation Conditions: adult Hodgkin's lymphoma; adult non-Hodgkin's lymphoma; Anxiety Disorder; childhood acute myeloid leukemia and other myeloid malignancies; ...
2.		Recruiting	CCI-779 in Treating Patients With Relapsed or Refractory Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
3.		Recruiting	Stem Cell Transplantation in Treating Patients With Previously-Treated Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
4.		Recruiting	Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
5.		Recruiting	Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
6.		Recruiting	Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
7.		Recruiting	Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis
8.		Recruiting	Antineoplaston Therapy in Treating Patients With Multiple Myeloma Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
9.		Recruiting	High-Dose Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Amyloidosis Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis
10.		Recruiting	Bortezomib and Liposomal Doxorubicin in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
11.		Not yet recruiting	Melphalan and Amifostine Followed By Stem Cell Transplantation in Treating Patients With Multiple Myeloma Conditions: Drug Toxicity; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
12.		Not yet recruiting	Dexamethasone With or Without CC-5013 in Treating Patients With Newly Diagnosed Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
13.		Recruiting	Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
14.		Recruiting	Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
15.		Recruiting	Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
16.		Recruiting	Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; Infection
17.		Recruiting	Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma Conditions: stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
18.		Recruiting	Tandem Autologous Stem Cell Transplantation With or Without Maintenance Therapy After the Second Transplantation Compared With Autologous Stem Cell Transplantation Followed By Matched Sibling Allogeneic Stem Cell Transplantation in Patients With Stage II or Stage III Multiple Myeloma Conditions: stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
19.		Recruiting	FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma Conditions: stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
20.		Recruiting	Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma Condition: Multiple Myeloma
21.		Recruiting	Study Comparing Skeletal Targeted Radiotherapy (STR) plus Melphalan to Melphalan Alone, with Stem Cell Transplant in Multiple Myeloma Condition: Multiple Myeloma
22.		Recruiting	Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma Condition: Multiple Myeloma
23.		Recruiting	A Study of PS-341 Given to Patients With Multiple Myeloma who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 Condition: Multiple Myeloma
24.		Recruiting	Study of Oral SCIO-469 in Relapsed, Refractory Patients with Multiple Myeloma Condition: Multiple Myeloma
25.		Recruiting	Combination Bisphosphonate and Anti-Angiogenesis Therapy with Pamidronate and Thalidomide Condition: Multiple Myeloma
26.		Recruiting	Combination Bisphosphonate and Anti-Angiogenesis Therapy with Pamidronate and Thalidomide Condition: Multiple Myeloma
27.		Recruiting	Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma Conditions: stage II multiple myeloma; stage III multiple myeloma
28.		Recruiting	High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis Conditions: primary systemic amyloidosis; stage II multiple myeloma; stage III multiple myeloma
29.		Recruiting	Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma Conditions: stage II multiple myeloma; stage III multiple myeloma
30.		Recruiting	Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma Conditions: stage II multiple myeloma; stage III multiple myeloma
31.		Recruiting	Safety and Efficacy of Atiprimod for Patients with Refractory Multiple Myeloma Condition: Multiple Myeloma
32.		Recruiting	Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally Condition: Multiple Myeloma
33.		Recruiting	Study of Combination PS-341 and Thalidomide in Multiple Myeloma Condition: Multiple Myeloma
34.		Recruiting	Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients with Relapsed Multiple Myeloma Condition: Multiple Myeloma
35.		Recruiting	Xcellerated T CellsTM in Patients with Multiple Myeloma Condition: Multiple Myeloma
36.		Recruiting	Combined Bone Marrow and Kidney Transplant for Multiple Myeloma with Kidney Failure Conditions: Kidney Failure, Chronic; Multiple Myeloma
37.		Recruiting	Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow Conditions: Hematologic Disease; Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome; Myeloproliferative Disorder
38.		Recruiting	2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors Conditions: refractory plasma cell neoplasm; stage III multiple myeloma; unspecified adult solid tumor, protocol specific
39.		Recruiting	Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II Condition: Multiple Myeloma
40.		Not yet recruiting	Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination with DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma Condition: Multiple Myeloma
41.		Recruiting	Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant Condition: Multiple Myeloma
42.		Recruiting	A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) Condition: Multiple Myeloma
43.		Recruiting	UARK 2003-33, Total Therapy III Condition: Multiple Myeloma
44.		Recruiting	Study of SGN-40 (anti-huCD40 mAb) in Patients with Refractory or Recurrent Multiple Myeloma Condition: Multiple Myeloma
45.		Recruiting	Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients with Multiple Myeloma Condition: Multiple Myeloma
46.		Recruiting	Double Cord Blood Transplant Study Conditions: Leukemia, Lymphocytic, Acute; Leukemia, Myelocytic, Acute; Leukemia, Myeloid, Chronic; Lymphoma, Non-Hodgkin; Multiple Myeloma
47.		Recruiting	Safety Study of AP23573 in Patients with Advanced, Refractory or Recurrent Malignancies Conditions: Tumors; Lymphoma; Multiple Myeloma
48.		Recruiting	Safety and pharmacokinetics of orally administered gallium maltolate in various refractory malignancies. Conditions: Prostatic Neoplasms; Multiple Myeloma; Bladder Neoplasms; Lymphoma
49.		Recruiting	Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H Conditions: Myelodysplastic Disorders; Leukemia; Multiple Myeloma; Plasma Cell Dyscrasia; Lymphoproliferative Disorders
50.		Recruiting	Blood and Marrow Transplant Clinical Research Network Conditions: Bone Marrow Transplantation; Blood Disease; Hematopoietic Stem Cell Transplantation; Leukemia; Multiple Myeloma; Myelodysplastic Syndromes; ...